{
    "clinical_study": {
        "@rank": "159868", 
        "arm_group": {
            "arm_group_label": "Melanoma patients on Ipilimumab", 
            "description": "All unresectable, recurrent or metastatic melanoma patients"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of the protocol is to identify and describe observed adverse events\n      (AEs) while on treatment with Ipilimumab for advanced melanoma in Venezuela during the study\n      period"
        }, 
        "brief_title": "Ipilimumab 12-month Intensive Pharmacovigilance Protocol", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com.\n\n        Inclusion Criteria:\n\n          -  Age of 18 years or older on date of first dose of Ipilimumab\n\n          -  Subjects who received at least 1 dose of Ipilimumab for the treatment of\n             unresectable, recurrent or metastatic melanoma in Venezuela\n\n        Exclusion Criteria:\n\n          -  Subjects who received Ipilimumab as part of a clinical trial\n\n          -  Subjects who received Ipilimumab for any indication other than local approval (ie,\n             unresectable or metastatic melanoma)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Bristol Myers de Venezuela S.A.C. has in place a Customer Model registry, which tracks\n        every Ipilimumab prescription in Venezuela. Therefore, any oncologist who treats a patient\n        with Ipilimumab will be identified by BMS. Use of this registry will ensure all patients\n        who are infused with Ipilimumab are included in this study"
            }
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02050594", 
            "org_study_id": "CA184-366"
        }, 
        "intervention": {
            "arm_group_label": "Melanoma patients on Ipilimumab", 
            "intervention_name": "Ipilimumab", 
            "intervention_type": "Drug", 
            "other_name": "Yervoy"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 29, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trials Disclosure", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "number_of_groups": "1", 
        "official_title": "Ipilimumab 12-month Intensive Pharmacovigilance Protocol", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "For Site information please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of email MUST contain NCT# & Site#. Only trial site that are recruiting have contact information at this time"
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Venezuela: CENAVIF (National Center for Pharmacovigilance)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Descriptive statistics of observed adverse events (AEs) while on treatment with Ipilimumab for advanced melanoma in Venezuela", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 12 months of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02050594"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "collaborator": {
                "agency": "JSS Medical Research Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}